These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 26845930)

  • 1. [Effects of telaprevir (TVR) on cholesterol metabolism].
    Nakamuta M; Kohjima M
    Nihon Rinsho; 2015 Dec; 73 Suppl 9():199-203. PubMed ID: 26845930
    [No Abstract]   [Full Text] [Related]  

  • 2. Pharmacokinetic and pharmacodynamic evaluation of telaprevir for the treatment of hepatitis C.
    Rivero-Juarez A; Camacho A; Rivero A
    Expert Opin Drug Metab Toxicol; 2015 Jul; 11(7):1157-65. PubMed ID: 26004270
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel polymerase inhibitors shape new HCV combinations with telaprevir.
    AIDS Patient Care STDS; 2009 Apr; 23(4):309-10. PubMed ID: 19358693
    [No Abstract]   [Full Text] [Related]  

  • 4. Inhibitory effects of Pycnogenol® on hepatitis C virus replication.
    Ezzikouri S; Nishimura T; Kohara M; Benjelloun S; Kino Y; Inoue K; Matsumori A; Tsukiyama-Kohara K
    Antiviral Res; 2015 Jan; 113():93-102. PubMed ID: 25446333
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical trial investigates two experimental HCV drugs.
    AIDS Patient Care STDS; 2010 Apr; 24(4):270. PubMed ID: 20402017
    [No Abstract]   [Full Text] [Related]  

  • 6. Boceprevir and telaprevir in the management of hepatitis C virus-infected patients.
    Butt AA; Kanwal F
    Clin Infect Dis; 2012 Jan; 54(1):96-104. PubMed ID: 22156853
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Daily low-dose tacrolimus is a safe and effective immunosuppressive regimen during telaprevir-based triple therapy for hepatitis C virus recurrence after liver transplant.
    Papadopoulos-Köhn A; Achterfeld A; Paul A; Canbay A; Timm J; Jochum C; Gerken G; Herzer K
    Transplantation; 2015 Apr; 99(4):841-7. PubMed ID: 25208324
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The face of future hepatitis C antiviral drug development: recent biological and virologic advances and their translation to drug development and clinical practice.
    McHutchison JG; Bartenschlager R; Patel K; Pawlotsky JM
    J Hepatol; 2006 Feb; 44(2):411-21. PubMed ID: 16364491
    [No Abstract]   [Full Text] [Related]  

  • 9. Targeting host lipid synthesis and metabolism to inhibit dengue and hepatitis C viruses.
    Villareal VA; Rodgers MA; Costello DA; Yang PL
    Antiviral Res; 2015 Dec; 124():110-21. PubMed ID: 26526588
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The efficacy and safety of telaprevir - a new protease inhibitor against hepatitis C virus.
    Gentile I; Carleo MA; Borgia F; Castaldo G; Borgia G
    Expert Opin Investig Drugs; 2010 Jan; 19(1):151-9. PubMed ID: 20001560
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lipid metabolite profiling identifies desmosterol metabolism as a new antiviral target for hepatitis C virus.
    Rodgers MA; Villareal VA; Schaefer EA; Peng LF; Corey KE; Chung RT; Yang PL
    J Am Chem Soc; 2012 Apr; 134(16):6896-9. PubMed ID: 22480142
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Management of Tacrolimus-Telaprevir Drug-Drug Interaction in a Liver Transplant Patient With Hepatitis C Virus: Practical Considerations.
    Pape E; Scala-Bertola J; Petitpain N; Jouzeau JY; Charrois-Sciaudeau S; Kemmel V; Barraud H; Gambier N
    Transplantation; 2015 Sep; 99(9):e163-4. PubMed ID: 26308424
    [No Abstract]   [Full Text] [Related]  

  • 13. Therapeutics: new drugs hit the target.
    Schlütter J
    Nature; 2011 Jun; 474(7350):S5-7. PubMed ID: 21666733
    [No Abstract]   [Full Text] [Related]  

  • 14. Telaprevir: a novel NS3/4 protease inhibitor for the treatment of hepatitis C.
    Klibanov OM; Williams SH; Smith LS; Olin JL; Vickery SB
    Pharmacotherapy; 2011 Oct; 31(10):951-74. PubMed ID: 21950642
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drugs in development for viral hepatitis: care and caution.
    Pockros PJ
    Drugs; 2011 Feb; 71(3):263-71. PubMed ID: 21319865
    [No Abstract]   [Full Text] [Related]  

  • 16. A Hepatitis C virus-host interaction involved in viral replication: toward the identification of antiviral targets.
    Suzuki T
    Jpn J Infect Dis; 2010 Sep; 63(5):307-11. PubMed ID: 20858994
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Telaprevir activity is unaffected by the Q80K polymorphism in hepatitis C virus genotype 1a.
    Shafran S
    Can J Gastroenterol Hepatol; 2014 Oct; 28(9):510. PubMed ID: 25314358
    [No Abstract]   [Full Text] [Related]  

  • 18. Evolution of treatment-emergent resistant variants in telaprevir phase 3 clinical trials.
    Sullivan JC; De Meyer S; Bartels DJ; Dierynck I; Zhang EZ; Spanks J; Tigges AM; Ghys A; Dorrian J; Adda N; Martin EC; Beumont M; Jacobson IM; Sherman KE; Zeuzem S; Picchio G; Kieffer TL
    Clin Infect Dis; 2013 Jul; 57(2):221-9. PubMed ID: 23575197
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Telaprevir: changing the standard of care of chronic hepatitis C.
    Rajani AK; Ravindra BK; Dkhar SA
    J Postgrad Med; 2013; 59(1):42-7. PubMed ID: 23525057
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Telaprevir: new possibilities for antiviral treatment in patients with chronic hepatitis C].
    Nikitin IG; Gogova LM; Baikova IE; Kislyakov VA; Volynkina VM
    Ter Arkh; 2012; 84(11):75-80. PubMed ID: 23252254
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.